EGFR is the first antitumor target to be identified, and known to be overexpressed in most of the TNBC and inflammatory breast cancers (Masuda et al., 2012), but associated with paradoxical function in metastatic cancer progression (Ali and Wendt, 2017). Here, EGFR is linked to inflammatory breast carcinoma.